Treatment of older patients with acute myeloid leukemia (AML): revised Canadian consensus guidelines.

about

Risk Factors for Invasive Fungal Infection among Thai Oncologic Patients with Febrile Neutropenia and Cutaneous Presentation: A 5-Year Retrospective Study in Southern Thailand

P2860

Q47235379-214F8113-8B6F-4DC5-B00C-15A54A17498E

P2860

Treatment of older patients with acute myeloid leukemia (AML): revised Canadian consensus guidelines.

Item

http://www.wikidata.org/entity/Q41265804

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Treatment of older patients wi ...... Canadian consensus guidelines.

@en

type

Item

label

Treatment of older patients wi ...... Canadian consensus guidelines.

@en

prefLabel

Treatment of older patients wi ...... Canadian consensus guidelines.

@en

P1476

Treatment of older patients wi ...... Canadian consensus guidelines.

@en

P2093

Andre C Schuh

http://www.w3.org/2001/XMLSchema#string

Harold J Olney

http://www.w3.org/2001/XMLSchema#string

Jeannine Kassis

http://www.w3.org/2001/XMLSchema#string

Joseph M Brandwein

http://www.w3.org/2001/XMLSchema#string

Mitchell Sabloff

http://www.w3.org/2001/XMLSchema#string

Mohamed Elemary

http://www.w3.org/2001/XMLSchema#string

Nancy Zhu

http://www.w3.org/2001/XMLSchema#string

Rajat Kumar

http://www.w3.org/2001/XMLSchema#string

P2860

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.

The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes

Treatment advances have not improved the early death rate in acute promyelocytic leukemia.

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

P304

30-40

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Irwindeep Sandhu

B Leber

P577

2017-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28804680

http://www.w3.org/2001/XMLSchema#string

P932

5545212

http://www.w3.org/2001/XMLSchema#string

Treatment of older patients with acute myeloid leukemia (AML): revised Canadian consensus guidelines.

about

P2860

P2860

Treatment of older patients with acute myeloid leukemia (AML): revised Canadian consensus guidelines.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P50

P577

P698

P932

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P50

P577

P698

P932